On April 30, 2020 MonTa Biosciences reported that recruits Chief Medical Officer Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong record of bringing oncology products forward into clinical development (Press release, MonTa Biosciences, APR 30, 2020, View Source [SID1234618626]). Steven will be supporting MonTa in the clinical development of MBS8 which is planned to enter clinical trial by the end of 2020. The board and management of MonTa Biosciences are very honoured to have such strong clinical expert to join the management team and contribute with years of experience in clinical development of new oncology technologies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!